| 000 | 01721 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516212751.0 | ||
| 264 | 0 | _c20150330 | |
| 008 | 201503s 0 0 eng d | ||
| 022 | _a1768-3254 | ||
| 024 | 7 |
_a10.1016/j.ejmech.2014.03.075 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuo, Xiaoke | |
| 245 | 0 | 0 |
_aDiscovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). _h[electronic resource] |
| 260 |
_bEuropean journal of medicinal chemistry _cJun 2014 |
||
| 300 |
_a89-94 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Discovery |
| 650 | 0 | 4 | _aHEK293 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKv1.5 Potassium Channel _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aMa, Xianglei | |
| 700 | 1 | _aYang, Qian | |
| 700 | 1 | _aXu, Jing | |
| 700 | 1 | _aHuang, Lu | |
| 700 | 1 | _aJia, Jianmin | |
| 700 | 1 | _aShan, Jiaojiao | |
| 700 | 1 | _aLiu, Li | |
| 700 | 1 | _aChen, Weilin | |
| 700 | 1 | _aChu, Hongxi | |
| 700 | 1 | _aWei, Jinlian | |
| 700 | 1 | _aZhang, Xiaojin | |
| 700 | 1 | _aSun, Haopeng | |
| 700 | 1 | _aTang, Yiqun | |
| 700 | 1 | _aYou, Qidong | |
| 773 | 0 |
_tEuropean journal of medicinal chemistry _gvol. 81 _gp. 89-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejmech.2014.03.075 _zAvailable from publisher's website |
| 999 |
_c23821792 _d23821792 |
||